3 Jul (PROPUBLICA) – On Monday, the Department of Justice announced that drug company GlaxoSmithKline agreed to pay a $3 billion fine, the largest health care fraud fine in the history of the United States.  This fine is just the latest in a string of drug company penalties for improper promotion of drugs for “off-label,” or unapproved, uses.  ProPublica takes a look at six recent multi-million dollar fines that drug companies have agreed to pay for inappropriately, and in some cases illegally, promoting prescription drugs.  STORY HERE.